¹³¹I-Metuximab (brand name Licartin) is a radiolabeled murine antibody developed for the treatment of hepatocarcinoma. The drug is targeting CD147 and was launched in China in 2006. The drug is only available in this country for the time being.

Target/Mechanism: CD147

Carrier/Ligand: Metuximab

Radiation Type: beta electrons (β^–)